Stocktoria
CATALYST PHARMACEUTICALS, INC. CPRX
CATALYST PHARMACEUTICALS, INC. (CPRX) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $589.0M at a 36.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -1.81 — grey zone (between the usual thresholds). A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-28 | HC Wainwright & Co. | Neutral (down) |
| 2026-05-08 | Citigroup | Neutral (down) |
| 2026-05-07 | Stephens & Co. | Equal-Weight (down) |
| 2026-03-03 | Citigroup | Buy (main) |
| 2025-11-07 | Citigroup | Buy (main) |
| 2025-03-03 | Baird | Outperform (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.677 |
| Retained earnings / assets | 0.43 |
| EBIT / assets | 0.233 |
| Equity / liabilities | 6.374 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CPRX | CATALYST PHARMACEUTICALS, INC. | 4/9 | 14.1 | 18 | +19.8% |
| INSM | INSMED Inc | 3/9 | -7.47 | — | +66.7% |
| OPK | OPKO HEALTH, INC. | 4/9 | -0.79 | — | -14.9% |
| ORGO | Organogenesis Holdings Inc. | 3/9 | 5.27 | 8.4 | +17% |
| TGTX | TG THERAPEUTICS, INC. | 4/9 | 2.04 | 19.1 | +87.3% |
| HCM | HUTCHMED (China) Ltd | 4/9 | 6.45 | 31.3 | -13% |
| AXSM | Axsome Therapeutics, Inc. | 4/9 | -5.64 | — | +65.5% |
About CATALYST PHARMACEUTICALS, INC.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
FAQ
Is CPRX financially healthy?
CATALYST PHARMACEUTICALS, INC.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does CPRX pay a dividend?
No, CATALYST PHARMACEUTICALS, INC. does not currently pay a dividend.
How profitable is CPRX?
In FY2025, CATALYST PHARMACEUTICALS, INC. had a net margin of 36.4% and a return on equity of 22.5%.
What is CPRX's P/E ratio?
CATALYST PHARMACEUTICALS, INC.'s trailing price-to-earnings (P/E) ratio is about 18.0×, based on its latest annual earnings.
What is the analyst price target for CPRX?
The average Wall-Street price target for CATALYST PHARMACEUTICALS, INC. is $31.67, from 3 analysts.
Is CPRX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on CATALYST PHARMACEUTICALS, INC.: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone, a P/E of about 18.0×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.